Sacubitril-Valsartan and Heart Function in End-stage Kidney Disease Trials have found that
sacubitril-valsartan reduces heart failure hospitalizations and mortality for patients with heart …

Background/Aim: Sacubitril/valsartan (SV), a novel pharmacological class of angiotensin
receptor neprilysin inhibitors, is effective in treating heart failure (HF) by inhibiting the …

Aim: To analyze the impact of sacubitril/valsartan on functional class, surrogate parameters
and clinical outcomes in clinical practice. Methods: Retrospective study of patients with heart …

Objective: The current meta-analysis reviews the different randomized controlled trials
(RCTs) on the use of sacubitril-valsartan (SV) thoroughly and assesses its effectiveness and …

Heart failure (HF) is a clinical syndrome with signs and symptoms that result from any
structural or functional deterioration of ventricular filling or ejection of blood. It is the final …

Introduction Patients with end-stage kidney disease (ESKD) frequently develop heart failure,
contributing to high mortality. Limited data exist on cardiovascular benefits and safety of …

Background: Sacubitril-valsartan has been shown to improve morbidity and mortality in heart
failure patients with reduced left ventricular (LV) ejection fraction (EF). However, there is little …

Background Limited evidence is available regarding low (24/26 mg) and middle (49/51 mg)
doses of sacubitril/valsartan. Objectives The purpose of this study was to investigate the …

There exists a paucity of research data reported by analyses performed on randomized
clinical trials (RCTs) that encompass quality of life (QOL) and the aftermath for patients …

Introduction The first publication of the PARADIGM-HF trial in 2014, for sacubitril/valsartan
(SV) has been a landmark trial to enable optimal use of ARNI and subsequently further …